193 related articles for article (PubMed ID: 32646991)
21. COVID-19 vaccine development pipeline gears up.
Mullard A
Lancet; 2020 Jun; 395(10239):1751-1752. PubMed ID: 32505245
[No Abstract] [Full Text] [Related]
22. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
Lodge A
Lancet; 2020 Nov; 396(10261):1486. PubMed ID: 33160564
[No Abstract] [Full Text] [Related]
23. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
Chauhan A; Agarwal A; Jaiswal N; Singh M
Lancet; 2020 Nov; 396(10261):1485-1486. PubMed ID: 33160563
[No Abstract] [Full Text] [Related]
24. [Not Available].
Red
MMW Fortschr Med; 2020 Apr; 162(7):56. PubMed ID: 32291653
[No Abstract] [Full Text] [Related]
25. After A COVID-19 Vaccine: Collaboration Or Competition?
Meyer H
Health Aff (Millwood); 2020 Nov; 39(11):1856-1860. PubMed ID: 32986500
[TBL] [Abstract][Full Text] [Related]
26. "Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy.
Graffigna G; Palamenghi L; Barello S; Stefania B
Vaccine; 2020 Nov; 38(48):7585-7586. PubMed ID: 33121655
[No Abstract] [Full Text] [Related]
27. Covid-19 elimination: consider population level effects of vaccine.
Payne N
BMJ; 2020 Oct; 371():m3889. PubMed ID: 33023934
[No Abstract] [Full Text] [Related]
28. An Inactivated Virus Candidate Vaccine to Prevent COVID-19.
Mulligan MJ
JAMA; 2020 Sep; 324(10):943-945. PubMed ID: 32789500
[No Abstract] [Full Text] [Related]
29. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.
Heininger U
Pediatr Infect Dis J; 2020 Jul; 39(7):e123-e124. PubMed ID: 32427644
[No Abstract] [Full Text] [Related]
30. Talk to Patients About: Why Will It Take So Long for a COVID-19 Vaccine?
Price S
Tex Med; 2020 Jun; 116(6):19. PubMed ID: 32645183
[TBL] [Abstract][Full Text] [Related]
31. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
Voysey M; Pollard AJ
Lancet; 2020 Nov; 396(10261):1486-1487. PubMed ID: 33160565
[No Abstract] [Full Text] [Related]
32. Authors' reply to Kolstoe and Hanna and colleagues.
van der Westhuizen HM; Kotze K; Tonkin-Crine S; Gobat N; Greenhalgh T
BMJ; 2020 Oct; 371():m3799. PubMed ID: 33008828
[No Abstract] [Full Text] [Related]
33. COVID-19 vaccine trials in Africa.
Makoni M
Lancet Respir Med; 2020 Nov; 8(11):e79-e80. PubMed ID: 32896275
[No Abstract] [Full Text] [Related]
34. Possible treatment of Covid-19 with a therapeutic vaccine.
Myint A; Jones T
Vet Rec; 2020 Apr; 186(13):419. PubMed ID: 32245869
[No Abstract] [Full Text] [Related]
35. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.
Abu-Raya B; Gantt S; Sadarangani M
CMAJ; 2020 Aug; 192(34):E982-E985. PubMed ID: 32646869
[No Abstract] [Full Text] [Related]
36. Facilitating Access to a COVID-19 Vaccine through Global Health Law.
Gostin LO; Karim SA; Mason Meier B
J Law Med Ethics; 2020 Sep; 48(3):622-626. PubMed ID: 33021168
[No Abstract] [Full Text] [Related]
37. Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.
Moise L; Ross TM; Hoft DF; Martin WD; De Groot AS
Expert Rev Vaccines; 2020 Sep; 19(9):781-784. PubMed ID: 32962468
[No Abstract] [Full Text] [Related]
38. COVID-19 vaccines: time to talk about the uncertainties.
Subbarao K
Nature; 2020 Oct; 586(7830):475. PubMed ID: 33082537
[No Abstract] [Full Text] [Related]
39. Russian SARS-CoV-2 vaccine.
Caddy S
BMJ; 2020 Aug; 370():m3270. PubMed ID: 32839191
[No Abstract] [Full Text] [Related]
40. The Russian vaccine for COVID-19.
Burki TK
Lancet Respir Med; 2020 Nov; 8(11):e85-e86. PubMed ID: 32896274
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
